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Although in vitro studies of embryonic stem cells
have identified polycomb repressor complexes
(PRCs) as key regulators of differentiation, it remains
unclear as to how PRC-mediated mechanisms
control fates of multipotent progenitors in devel-
oping tissues. Here, we show that an essential PRC
component, Ezh2, is expressed in epidermal progen-
itors but diminishes concomitant with embryonic
differentiation and with postnatal decline in prolifera-
tive activity. We show that Ezh2 controls proliferative
potential of basal progenitors by repressing the
Ink4A-Ink4B locus and tempers the developmental
rate of differentiation by preventing premature
recruitment of AP1 transcriptional activator to the
structural genes that are required for epidermal
differentiation. Together, our studies reveal that
PRCs control epigenetic modifications temporally
and spatially in tissue-restricted stem cells. They
maintain their proliferative potential and globally re-
pressing undesirable differentiation programs while
selectively establishing a specific terminal differenti-
ation program in a stepwise fashion.
INTRODUCTION
One of the fundamental goals of modern biology is to understand
the molecular mechanisms by whichmultipotent progenitor cells
control tissue development and maintenance. Increasing
evidence has pointed to a possible role for polycomb group
(PcG) proteins in this process. PcG proteins form chromatin-
remodeling complexes referred to as polycomb repressor
complexes (PRCs) (Ringrose and Paro, 2004). Comprised of1122 Cell 136, 1122–1135, March 20, 2009 ª2009 Elsevier Inc.Ezh2, Eed, and Suz12, PRC2 is recruited to chromatin, where
methyltransferase Ezh2 catalyzes H3 trimethylation on lysine
27 (triMeK27-H3) (Cao et al., 2002). This histone mark then
provides a platform to recruit PRC1 (Cao et al., 2002; Min
et al., 2003), which aids in PcG-mediated repression either by
chromatin compaction or by interfering with the transcription
machinery (Francis et al., 2004; Ringrose and Paro, 2004; Sarma
et al., 2008). Without Ezh2 activity, PRC1 cannot be recruited to
chromatin, and PcG-mediated repression is not established
(Cao et al., 2002; Rastelli et al., 1993).
In vitro studies of pluripotent mouse and human embryonic
stem cells (ESCs) have shown that PRC2 proteins and their
triMeK27-H3 marks reside at and transcriptionally repress many
regulatory genes that control specific developmental lineages
(Boyer et al., 2006; Lee et al., 2006; Pietersen and van Lohuizen,
2008). Establishing functional significance, Eed null ESCs have
elevated expression of PcG-repressed differentiation genes
(Boyer et al., 2006; Chamberlain et al., 2008).
Intriguingly, the genes in ESCs that are repressed by
triMeK27-H3 frequently contain the additional H3 modification,
lysine 4 trimethylation (triMeK4-H3), often associated with active
chromatin (Bernstein et al., 2006). This has led to speculation
that, through these bivalent marks, differentiation genes
controlled by PRC2 may be poised for activation upon removal
of their repressive epigenetic marks (Bernstein et al., 2006;
Boyer et al., 2006). That said, the role of PRC-mediated chro-
matin repression in regulating ESC differentiation is complex.
Thus, cultured Suz12 null ESCs treated with retinoic acid do
not execute normal neuronal differentiation but, rather, fail to
suppress pluripotent genes and only partially activate neuronal
genes (Pasini et al., 2007). This has led to speculation that
PRCs are required for both suppression and activation of differ-
entiation programs in ESCs.
It remains an important challenge to determine whether these
epigenetic mechanisms unveiled in vitro operate in vivo to
govern fates of the more restricted progenitors that develop
and maintain tissues (Spivakov and Fisher, 2007). Assessing the
roles of PcG components in tissue organogenesis has been
hampered by the early embryonic lethality caused by loss-of-
function mutants of core PRC2 components. Conversely and
further complicating interpretation is that conditional ablation
of Ezh2 in adult bone marrow cells does not seem to affect either
hematopoietic SC survival or lineage determination, suggesting
either functional redundancy and/or compensation by paralo-
gous PRC genes in at least some tissues (Su et al., 2003,
2005). This also seems to be the case for PRC1 genes such as
Bmi1, in whichmutations do not appear to affect embryogenesis
(Sauvageau and Sauvageau, 2008; Valk-Lingbeek et al., 2004).
Ironically, Bmi1 mutants malfunction in maintaining hematopoi-
etic and neuronal adult SC renewal, in part due to misregulation
of the Ink4A/Arf locus (Bruggeman et al., 2005; Molofsky et al.,
2003, 2005; Park et al., 2003). That said, triMeK27-H3 epigenetic
marks are still apparent in Bmi1 null cells (Cao et al., 2005), sug-
gesting that the phenotype does not reflect complete abrogation
of PcG-repressive functions. These findings underscore the
importance of analyzing PcG functions in other in vivo biological
systems in order to understand their physiological relevance in
tissue development and maintenance.
Mammalian epidermis is an excellent model to address this
problem. Epidermal lineages originate froma single layer ofmulti-
potent progenitors, basal cells, that adhere toanunderlyingbase-
mentmembraneseparatingepidermis fromdermis (Fuchs, 2007).
In mice, epidermal stratification and fate specification initiate at
approximately embryonic day 14 (E14) and complete shortly
before birth, when the skin surface barrier is required to keep
harmful microbes out and prevent dehydration (Fuchs, 2007).
Basal cells continually fuel the production of 10 suprabasal
layers. Once cells exit the basal layer, they downregulate prolifer-
ation-associated genes and execute a terminal differentiation
program that is marked by a stepwise transcriptional transition
fromearlydifferentiationspinous layers to latedifferentiationgran-
ular layers. In the last step, all metabolic activity ceases as dead
squames of the protective stratum corneum are formed and
subsequently sloughed from the skin surface (Watt et al., 2006).
In this report, we use epidermis as amodel to explore the func-
tional significance and physiological relevance of PcG-mediated
chromatin repression during embryonic tissue development and
homeostasis. We unveil Ezh2 as a critical mediator of chromatin
repression in embryonic basal cells and show that its expression
diminishes with age and with commitment to terminally differen-
tiate in vivo and in vitro. Using chromatin immunoprecipitation
(ChIP) performed on purified embryonic epidermal progenitors,
we show that its triMeK27-H3 mark is present both on silent
epidermal genes activated late in terminal differentiation and
on nonepidermal genes, e.g., neuronal and muscle transcrip-
tional regulators. Interestingly, however, despite this broad
association of triMeK27-H3 with silenced genes of different
tissue lineages, loss of PcG-mediated repression does not alter
the fate of epidermal cells. Rather, it reduces their proliferation
through upregulation of the Ink4A-Ink4B locus and tempers
differentiation rates and barrier function acquisition by upregu-
lating late-stage epidermal differentiation genes, many of which
are controlled by AP1 transcriptional activators. We show that
the triMeK27-H3 mark prevents AP1 proteins from binding tothese target genes in basal cells and that, during terminal differ-
entiation, these late differentiation genes lose their histone mark,
associate with AP1 components, and become activated supra-
basally. Our findings provide new mechanistic insights into
PcG-mediated repression of tissue-specific differentiation
genes and suggest that the spatial balance between expression
of PcG epigenetic repressors in undifferentiated cells and tran-
scriptional activators like AP1 in differentiated cells controls
proper establishment of the stepwise mechanism of epidermal
differentiation during skin development.
RESULTS
Ezh2 Marks the Progenitor Cell Nuclei in Developing
Epidermis
At E14, epidermis consists of a basal layer of progenitors and
a layer of suprabasal cells that have initiated a program of
terminal differentiation but are still proliferative (Figures S1A
and S1B available online) (Lechler and Fuchs, 2005; Watt et al.,
2006). Purification of these two populations by fluorescence-
activated cell sorting (FACS) and transcriptional profiling
revealed that PcG components of PRC2 (Ezh2 and Eed) and
PRC1 (Bmi1, Cbx2, and Pcgf2) are expressed in basal cells
and downregulated suprabasally. Semiquantitative PCR
(RT-PCR) and anti-Ezh2 immunofluorescence confirmed these
patterns (Figures 1A and 1B and data not shown).
ByE16–E18,proliferation is restricted to thebasal layer, and the
epidermis consists of multiple layers of differentiating suprabasal
cells (Figures S1C and S1D). At these stages, Ezh2 was strong in
basal but weak in spinous, granular, and stratum corneum layers
(Figures 1C). After birth, Ezh2waned, and by postnatal day 9 (P9),
Ezh2 was barely detected even in basal cells (Figure 1D). The
5-Bromo-20-deoxyuridine (BrdU) pulses administered at different
developmental ages revealed that the% BrdU(+) basal cells also
decreased steadily with age (Figure 1E) and that the few remain-
ing Ezh2(+) cells were also BrdU(+) (Figure 1F).
In vitro, cultured basal epidermal cells exposed to elevated
calcium stop proliferating and initiate terminal differentiation
(Hennings et al., 1980). Similar to their behavior in vivo, basal
mouse keratinocytes (MK) expressed high levels of PcG mRNAs
and protein, which progressively declined upon calcium-
induced differentiation (Figures 1G and 1H). Both in vivo and
in vitro, Ezh2 in proliferating, undifferentiated MK was largely, if
not solely, nuclear (Figures 1I and 1J). Therefore, we pursued
the notion that, in epidermal MK, Ezh2 functions in the nucleus.
PcG-Dependent triMeK27-H3 Globally Marks Genes
of Nonepidermal Lineages and Selectively Marks Genes
of Epidermal Lineages
In mouse ESCs, PRC2 marks and globally represses genes
involved in the specification of lineages, including those of the
epidermal lineage (Boyer et al., 2006). To evaluate the extent to
which the repressedPRC2 targetsofmouseESCsaremaintained
in Ezh2(+) embryonic epidermis, we performed ChIP assays with
FACS-purified embryonic epidermal basal cells and Abs against
triMeK27-H3 and unmodified histone H3 (Figures S2A and S2B).
We first focused on nonepidermal ‘‘master’’ transcriptional regu-
lators of theHox, neuronal (Neurog1, Neurog2,Olig2, andOlig3),Cell 136, 1122–1135, March 20, 2009 ª2009 Elsevier Inc. 1123
Figure 1. Ezh2 Marks Basal Cell Progenitors in Developing Epidermis
(A) Differential expression of PcG components in E14 epidermis. FACS-purified basal and suprabasal cells were analyzed by semiquantitative RT-PCR of their
isolated mRNAs. Data are mean ± SD. n = 3. *p < 0.05.
(B–F) Age-related decline in basal Ezh2 correlates with reduced proliferative potential. BrdU was administered 4 hr prior to sacrificing mice. Frozen skin sections
were subjected to immunofluorescence microscopy. Primary Abs are color coded according to their secondary Abs. Nuclei are stained with Dapi (blue).
(G) Semiquantitative RT-PCR reveals decreased expression of PcG components with epidermal terminal differentiation in vitro. Primers against HPRTwere used
for normalization. Data are mean ± SD. n = 2. *p < 0.05.
(H) Ezh2 protein diminishes upon calcium (Ca)-induced MK differentiation in vitro. Controls are actin (unchanged) and K10 (spinous marker).
(I–J) Immunofluorescence and western blot analyses show Ezh2 nuclear localization and partitioning. Note that the cytosolic fraction (C) contains minor residual
nuclear material as judged by H3, whereas the nuclear fraction (N) is clean as judged by the absence of b-tubulin.
B, basal. SB, suprabasal. Der, dermis. HF, hair follicle. b4, b4 integrin. Scale bars, 30 mm.1124 Cell 136, 1122–1135, March 20, 2009 ª2009 Elsevier Inc.
and muscle (Myod1) families that are marked for PcG-mediated
repression in ESCs (Boyer et al., 2006). Many of these genes
were also transcriptionally repressed by triMeK27-H3 in basal
epidermal cells (Figures 2A and 2B).
We next focused on identifying epidermal lineage genes tar-
geted by PcG repression in Ezh2(+) embryonic basal cells. For
these studies, we analyzed promoters of basal genes, which
are transcriptionally active, as well as spinous and granular layer
genes, which are not expressed at this stage of differentiation.
Our tests includedgenespreviously found in ESCs to be enriched
for PcG-mediated repression, as well as other epidermal genes.
Interestingly, genes enriched for triMeK27-H3 in embryonic
basal cells showed a good inverse correlation between Ezh2
and terminal differentiation (Figures 2C and 2D) (Fuchs, 2007).
Genes coexpressed with Ezh2 in either embryonic basal or early
(spinous) layers (actinb1,K14,K1, andK10) were not enriched for
triMeK27-H3 in basal progenitors, whereas genes expressed in
granular cells (loricrin, filaggrin, Lce1, Lce1a2, andCrct1) showed
significant triMeK27-H3 enrichment in embryonic basal cells.
Intriguingly, the triMeK27-H3 status of genes in the embryonic
basal epidermal layer in vivo differed from that in cultured ESCs,
in which both early (K1) and late epidermal differentiation genes
(loricrin and Lce1a2) scored as targets of PcG-mediated repres-
sion (Boyer et al., 2006). Thus, whereas some PcG targets estab-
lished in pluripotent cells appear to be maintained in the
epidermal lineage, others may lose their repressive mark during
tissue development.
Ezh2 Controls Proliferation of Basal Cells through
Repression of Ink4A/Ink4B
To address the physiological significance of Ezh2’s interesting
pattern of gene expression, we conducted conditional loss-of-
Figure 2. In Embryonic Basal Progenitors,
triMeK27-H3 Marks Silenced Differentia-
tion-Specific Genes of Both Epidermal and
Nonepidermal Lineages
(A and C) ChIP analysis showing association of tri-
MeK27-H3 and bulk H3 with promoters of nonepi-
dermal and epidermal genes in FACS-purified E16
basal progenitors. Semiquantitative PCR of the
basal K5 gene promoter region was used for
normalization. Data are mean ± SD. n = 2.
(B and D) RT-PCR of nonepidermal and epidermal
mRNAs in E16 basal cells (BL) versus total
epidermis from P0 embryos. Negative control is
PCR with total RNA (RT) as a template. RT-PCR
with RNAs isolated from skeletal muscle and brain
served as positive controls (+Cont) for Myod1
(muscle) and Olig2 (brain). Control is HPRT
(unchanged).
function studies. Mice harboring the
floxed Ezh2 allele (Su et al., 2003) were
bred tomice expressingCre recombinase
under the keratin 14 (K14) promoter in
embryonic epidermal progenitors
(Vasioukhin et al., 1999). Ezh2 conditional
knockout (Ezh2 cKO) mice were born alive and in the expected
Mendelian ratios. Immunofluorescence and western blot anal-
yses revealed a loss of Ezh2 and triMeK27-H3 marks in basal
cells (Figures 3A–3C and S3A), underscoring their reliance
upon Ezh2 for establishment and maintenance of this mark.
TriMeK27-H3 was still detected in suprabasal cells, most likely
because the Ezh2 paralog, Ezh1, is expressed throughout
embryonic epidermis and in basal cells of postnatal skin
(Figure S8A). We return to this issue later.
In the absence of Ezh2, basal epidermal cells were less prolif-
erative, exhibiting reductions in Ki67(+) cells and BrdU labeling
(Figures 3D–3F). During early postnatal development when
Ezh2 was still expressed in WT basal cells, the % BrdU(+) basal
cells in Ezh2 cKO skin was more than 2-fold diminished. As Ezh2
waned in postnatal WT basal cells, the % BrdU(+) basal cells
within cKO and WT skins became comparable (Figure 3F).
When cultured, P0 Ezh2 cKO and WT basal cells both formed
similar-sized colonies with comparable efficiencies (Figures S3B
and S3C). However, whereas WT colonies were composed of
tightly packed small cells, cells within cKO colonies were often
larger, flat, and loosely packed (Figure 3G). After several days
in culture, the growth of Ezh2 cKO cultures began to slow
(Figure 3H). This reduction did not appear to be attributable to
increased apoptosis (Figure 3J) nor to altered growth factor-
stimulated actin dynamics (Su et al., 2005) (Figure 1). Instead,
cell-cycle analysis revealed an increase in G1/G0 and decrease
in S phase cKO cells compared toWT (Figure 3I). Consistent with
a reduction in S phase entry, the phosphorylation of retinoblas-
toma protein was reduced in cKO cells (Figure S3D).
The proliferation defect in Ezh2 cKO skin appeared to be
attributed, at least in part, to derepression of the Ink4B-Arf-
Ink4A tumor suppressor locus that encodes potent cell-cycleCell 136, 1122–1135, March 20, 2009 ª2009 Elsevier Inc. 1125
Figure 3. A Developmental Role for Ezh2 in the Proliferative Potential of Epidermal Progenitors
(A–C) Immunofluorescence and western blot reveal the absence of Ezh2 and triMeK27-H3 in P0 Ezh2 cKO basal cells.
(D and E) Immunofluorescence shows fewer Ki67 and BrdU(+) basal cells in P0 Ezh2 cKO epidermis.
(F) Quantification of BrdU(+) basal cells from mice receiving a 4 hr BrdU pulse at indicated times. Data are mean ± SD. WT, cKO n = 3–6. *p < 0.05.
(G–J) Differences in morphologies, growth rates, and cell cycles, but not apoptosis (active caspase 3, Ac-Cas3), of WT versus Ezh2 cKO epidermal cells in vitro.
Cell-cycle data are mean ± SD. WT, cKO n = 3. *p < 0.05.
(K–L) Semiquantitative RT-PCR to measure Ink4A and/or Ink4B expression in FACS-purified basal cells in vivo (K) or cultured 1 MK in vitro (L). Data are mean ±
SD. n = 2 for in vivo and n = 3 for in vitro analysis. *p < 0.05. For comparative purposes, WT expression in differentiating cells was determined by analyzing total
epidermal mRNA. The HPRT gene was used for all normalizations.
MK, mouse keratinocytes. F, feeders. Scale bar, 30 mm.inhibitors of the G1-to-S transition in a variety of cell types,
including epidermis (Bracken et al., 2007; Bruggeman et al.,
2007; Kim and Sharpless, 2006). Consistent with prior studies
that established Ink4B-Arf-Ink4A as a PcG target, we observed
an 10-fold upregulation of Ink4B in FACS-purified Ezh2 cKO
cells in vivo (Figure 3K) and a similar marked upregulation of
both Ink4A and Ink4B genes in Ezh2 null MK in vitro
(Figure 3L). Finally, in WT skin, Ink4B expression inversely corre-
lated with Ezh2 (Figure 3K, basal versus total).
Ezh2 Tempers Epidermal Development and Barrier
Acquisition
P0 Ezh2 cKO epidermis displayed a hyperthickened stratum cor-
neum and pronounced granular layer accompanied by the
expansion of the granular markers loricrin and filaggrin (Figures1126 Cell 136, 1122–1135, March 20, 2009 ª2009 Elsevier Inc.4A–4C). These defects were also apparent in E16 cKO skin
concomitant with loss of Ezh2 and basal triMeK27-H3 (Figures
4D–4F, S4A, and S4B). Ultrastructurally, the immature large ker-
atohyalin granules (KG) ofWT E16 skin were already dispersed in
cKO skin (Figures 4G and S4C) (Fuchs, 2007; Steven et al.,
1990). A well-formed stratum corneum was also evident, and
with proper preservation, highly ordered lipid lamellae intercon-
nected these cells only within the E16 Ezh2 cKO (Figure S4D).
Correspondingly, the nonepidermal periderm (P) layer that nor-
mally provides a temporary barrier during epidermal maturation
was already degenerated (Figures 4D, 4G, and S4C). These
various signs of accelerated development (Jaubert et al., 2003;
Patel et al., 2006) were manifested functionally in the precocious
acquisition of the epidermal barrier capable of excluding dye
(Figure 4H).
Figure 4. A Role for Ezh2 in Regulating Temporal Differentiation and Epidermal Barrier Acquisition during Skin Development
(A–F) Histological and immunofluorescence microscopy reveals signs of accelerated epidermal differentiation in P0 and E16 Ezh2 cKO epidermis. Semithin
sections in (A) and (D) are toluidine blue stained. Frozen sections are labeled with Abs as indicated (color coding according to secondary Abs).
(G) Ultrastructural analyses. Note the presence of mature keratohyalin granules (KG), a thin stratum corneum layer (SC), and a partial loss of periderm (P) in Ezh2
cKO E16 epidermis, all lacking in the WT counterpart.
(H) Blue dye exclusion assay to measure skin barrier.
Lor, Loricrin. Flg, filaggrin. BL, basal layer. Sp, spinous layer. Gr, granular layer. Der, dermis. Scale bar, 30 mm.Ezh2 Is Required to Repress Precocious Epidermal Late
Differentiation Genes in Basal Cells
To understand how loss of Ezh2 might result in accelerated
epidermal differentiation, we conducted transcriptional profiling
of FACS-purified basal cells from E16 Ezh2 cKO andWT skins to
determine the global consequences of Ezh2 loss to epidermal
gene expression. The data are compiled in Figure 5A, with upre-
gulated genes in red and downregulated genes in green.
As expected, loss of Ezh2 resultedmostly in gene upregulation
in basal cells. Surprisingly, however, only a small fraction of the
genes analyzed showed a more than 2-fold change compared
toWT. Of the 94 genes (0.2%) upregulated, 75%were epidermal
genes, and among the others, there did not appear to be a signif-
icant bias toward any specific developmental lineage (Table S1).Thus, despite the global association of triMeK27-H3 marks with
epidermal and nonepidermal genes (Figures 2A and 2C), the loss
of Ezh2 in basal cells led primarily to selective upregulation of
epidermal genes. In this regard, PRC-mediated repression in
basal epidermal cells appeared to differ markedly from ESCs,
in which PRC target genes encompassing multiple lineages
were upregulated when PcG function was compromised (Boyer
et al., 2006).
As judged by array and RT-PCR, genes associated with
basal and/or early (spinous) differentiation were unaffected by
loss of Ezh2 (Figures 5B and 5C), and this was consistent
with the lack of triMeK27-H3 marks at their promoters
(Figure 2C). Notably, this included transcription factors, e.g.,
Trp63, Tcf3, Notch, Hes1, AP2, cEBP, and Klf4, that haveCell 136, 1122–1135, March 20, 2009 ª2009 Elsevier Inc. 1127
Figure 5. Transcriptional Profiling and Chromatin Analyses Reveal Late Differentiation Genes as Direct Functional Targets of Ezh2 Repres-
sion in Embryonic Basal Cells
(A and B) Heatmap derived from cluster analysis of microarray data of E16 basal progenitors shows that genes whose expression is normally associated with late-
stage terminal differentiation are elevated in the absence of Ezh2. E18WT epidermis is used as a comparative source of genes active in late-stage terminal differ-
entiation. Microarray hybridizations for each sample were done in duplicate and are shown as separate columns. Probesets were selected that demonstrate
a 2 log change (in either direction) and present (‘‘P’’) in both instances of a condition (P in both KO or P in both WT). Red, overexpressed genes. Green, under-
expressed genes. No obvious changes were revealed in the basal expression of key epidermal transcriptional regulators when Ezh2 was absent (B).
(C) Semiquantitative RT-PCR of mRNAs from FACS-purified E16 basal progenitors confirms the precocious induction of late differentiation genes when Ezh2 is
absent. Semiquantitative RT-PCR with primers against the HPRT gene was used for normalization. Data are mean ± SD. n = 2. *p < 0.05.1128 Cell 136, 1122–1135, March 20, 2009 ª2009 Elsevier Inc.
been implicated in either maintenance of the undifferentiated
state or induction of terminal differentiation (Fuchs, 2007;
Watt et al., 2006). This finding also contrasted with ESCs, in
which many targets for global PcG repression of lineages are
transcriptional regulators of fate specification and differentia-
tion (Boyer et al., 2006).
Interestingly, 77% of genes upregulated in E16 Ezh2 cKO
basal cells were expressed more than 2-fold higher in mature
WT epidermis compared to WT basal cells (Figure 5A). More-
over, genes upregulated in Ezh2 null basal cells were primarily
those expressed during the normal course of terminal differenti-
ation. The largest differenceswere among genes encodingmajor
granular proteins, e.g., filaggrin (Flg), loricrin (Lor), involucrin (Ivl),
and late cornified envelope (Lce) proteins (Figures 5A and 5C and
Table S1) (Marshall et al., 2001; Watt et al., 2006). Notably, these
genes arewithin a 2Mb locus encompassing an epidermal differ-
entiation complex (EDC) on mouse chromosome 3 (Figure 5D).
These data suggest a role for Ezh2 in ensuring that granular
genes within this cluster are repressed until the appropriate
stage in development and differentiation.
Studies with cultured Ezh2 null MK provided further evidence
to support this notion. Thus, under low calcium conditions that
favor the basal fate, filaggrin and loricrin levels were comparable
to those ofWT cells exposed to high calcium, a trigger of terminal
differentiation (Figure S5A). In Ca2+-stimulated Ezh2 null MK,
filaggrin and loricrin were even more highly expressed than
normal.
To determine the extent to which precocious induction of late-
stage differentiation-specific genes in Ezh2 null basal cells is
a direct cell autonomous consequence of loss of Ezh2-mediated
repression, we conducted ChIP assays with Ezh2, triMeK27-H3,
and pan-H3 Abs and primers encompassing loricrin, filaggrin,
and other EDC gene promoters. In WT MK, both Ezh2 and
triMeK27-H3 were enriched near transcriptional initiation sites
(Figures 5E and S5B). The signals for both Ezh2 and triMeK27-
H3 appeared to be specific, as judged by comparisons with
Ezh2 null cells or control ChIPs in which Abs were omitted
(Figures 5E, S5B–S5D).
Basal cell PcG complexes were detected over many, but not
all, terminal differentiation-specific genes across the EDC locus
(Figure 5E). The distal region harboring the Lce genes was
particularly rich in triMeK27H3, whereas the small proline-rich
(Sprr) family of genes exhibited only background levels of this
modification (Figure 5E). Correspondingly, expression of Sprr
genes was unchanged (Figure 5A), suggesting that Ezh2 may
differentially regulate EDC genes. Promoters of basally ex-
pressed K14 and actinb1 genes and nonexpressed intergenic
regions did not display the Ezh2-mediated triMeK27-H3 mark
(Figure 5E). These findings underscored the specificity of the
ChIP signals and PcGs for late-stage differentiation genes and
established them as direct targets for Ezh2-histone methyltrans-
ferase.More to Gene Repression Than triMeK27-H3: Analysis
of Nonepidermal Genes
If expression of genes that receive triMeK27-H3 marks is gov-
erned solely by PRC-mediated chromatin modifications, then
relief of these marks should result in their aberrant activation.
We tested this by first examining the expression status of none-
pidermal genes harboring this histone mark in WT epidermal
cells and in ESCs (Figure 2A). Consistent with the global reduc-
tion of triMeK27-H3 when Ezh2 is absent, most of the nonepider-
mal genes that were analyzed showed a significant reduction in
triMeK27-H3 in Ezh2 null MK (Figure S5E). Despite the loss of
PcG repression, however, these genes were not activated
(Figure S5F).
More to Gene Expression Than triMeK27-H3: Analysis
of Epidermal Genes
To understand why relief of PcG repression leads to selective
activation of epidermal, but not nonepidermal, lineage genes in
our Ezh2 cKO mice, we began by investigating whether EDC
genes in basal cells selectively contain the active epigenetic
mark triMeK4-H3, known to function antagonistically in PcG-
regulated genes in ESCs (Bernstein et al., 2006). Although
triMeK4-H3 was readily detected at the promoters of naturally
expressed basal genes, we did not detect it in the EDC
promoters that we analyzed in embryonic basal cells (Figure 6A).
We next turned to the possibility that the counteractive mark in
epidermal basal cells might be a transcriptional activator
involved in regulating EDC gene expression. In searching for
key EDC gene regulator(s) that might be expressed basally in
WT cells, we began to focus on AP1 family members, which
are known to regulate loricrin and filaggrin promoter activities
(DiSepio et al., 1995; Jang et al., 1996). Genome scans revealed
AP1 consensus binding sites throughout the EDC cluster
(Figure 6B). Importantly, Jun and Fos AP1 proteins were
detected both in basal cells and total epidermis (Figures 6C,
6D, and S6A), and terminal differentiation appeared to elicit an
upregulation of some, but not all, AP1 proteins in vivo and
in vitro (Figures 6C and 6D).
To test whether AP1 factors might account for upregulation of
EDC genes upon loss of Ezh2, we used the chemical inhibitor
Tanshinone IIA (TanIIA), which is thought to abrogate all AP1
binding to DNA. In the absence of TanIIA and in low calcium,
only Ezh2 null and not WT basal MK expressed the EDC genes
(Figure 6E). The addition of TanIIA revealed a dose-dependent
reduction in expression of EDC genes that harbored AP1
consensus sites, but not in K14 and Ppib genes that lacked
them (Figure 6E). The inhibitory response to TanIIAwas observed
even for some EDC genes that lacked obvious AP1 sequence
motifs. Although consensus sequences are not always neces-
sary for DNA binding, an alternative possibility is that close
proximity of genes within this cluster contributes to their coordi-
nate regulation through shared regulatory elements. Although(D) Schematic representation of the epidermal differentiation cluster (EDC) onmouse chromosome 3. Late-stage differentiation EDC genes that were upregulated
in Ezh2-deficient basal cells are marked in red.
(E) ChIP analyses reveal the presence of triMeK27-H3 at promoters of many genes within the EDC in WT and reduction in Ezh2 cKO cells. Semiquantitative PCR
with primers against the promoter of the active K5 gene was used for normalization. Data are mean ± SD. n = 2. *p < 0.05.Cell 136, 1122–1135, March 20, 2009 ª2009 Elsevier Inc. 1129
Figure 6. Transcriptional Activator AP1, Rather Than Activating Histone Modifications, Governs Upregulation of EDC Genes in Ezh2 cKO
Basal Cells
(A) ChIP analyses show no association of the active triMeK4-H3 mark with EDC genes in WT embryonic basal cells, in which the EDC is silent. Semiquantitative
PCR with primers against the intergenic region on chromosome 5 was used for normalization. The basal K5 gene was used as a positive control. Data are mean ±
SD. n = 2.
(B) AP1 consensus sites are found at promoters of EDC genes.
(C and D) Semiquantitative RT-PCR and western blotting detects Jun and Fos AP1 proteins in epidermis and cultured MK. Expression of some members is
enhanced in terminally differentiating cells. Positive control is HPRT (unchanged) and Flg (differentiated layers). Data are mean ± SD. n = 2. *p < 0.05.
(E and F) Semiquantitative RT-PCR shows that the precocious activation of EDC genes in Ezh2 cKO basal progenitors is largely abrogated by either the AP1
inhibitor, TanIIA, or RNAi-mediated attenuation of cJun/JunD expression. Data are mean ± SD. n = 2. *p < 0.05.1130 Cell 136, 1122–1135, March 20, 2009 ª2009 Elsevier Inc.
pursuing this further is outside the scope of the present study,
such a mechanism has been shown for other gene complexes
(Dillon and Grosveld, 1993; Lomvardas et al., 2006).
To verify that EDC gene expression in Ezh2 null basal cells is
AP1 dependent, we used RNAi to attenuate expression of Jun
proteins, which can homodimerize or form heterodimers with
Fos. cJun and JunD shRNAs each led to specific downregulation
of EDC genes without affecting K14 or Ppib expression (Figures
6F and S6B). Combination of both shRNAs was even more
dramatic, yielding comparable EDC gene expression levels
between WT and cKO basal cells (Figure 6F).
Conversely PMA, which facilitates AP1 activity (Eckert et al.,
1997), had little or no effect on EDC gene expression inWT basal
cells, but in Ezh2 null cells, PMA further enhanced activation of
EDC genes in low-calcium conditions (Figure 6G). By contrast,
expressionof PcG-repressednonepidermal genesMyod1,Olig2,
and HoxB13 were unaffected by PMA (Figure S6C). Finally, PMA
resulted only in a very modest upregulation of EDC genes when
Ezh2 cKO basal cells were exposed to Jun shRNAs (Figure 6H).
Together, these loss- and gain-of-function studies demonstrate
that, in basal epidermal cells, EDC genes are repressed by
Ezh2 even though AP1 transactivating factors are present.
Consistent with our array data (Figure 5B), Ezh2 did not mark-
edly affect AP1 mRNA or protein levels either in vivo or in vitro
(Figure S7). Thus, we speculated that triMeK27-H3 marks on
EDC genes in WT basal cells may interfere with AP1 recruitment,
as it has been shown for Myod1 in muscle cells in vitro (Caretti
et al., 2004). To test this hypothesis, we first analyzed whether
coordinated relief of triMeK27-H3 and recruitment of AP1 factors
control terminal differentiation and EDC gene expression under
normal physiological conditions. Of the EDC genes marked by
Ezh2 and triMeK27-H3, all but Lce3b were significantly upregu-
lated when basal MK were induced to differentiate (Figure 7A)
(Jackson et al., 2005). ChIP analysis of triMeK27-H3 at the
EDC cluster detected a significant decrease in this repressive
mark concomitant with EDC gene activation (Figure 7B).
Finally, ChIP analysis detected cJun at several EDC gene
promoters only in cKOandnotWTbasal cells (Figure 7C). By con-
trast, cJun was not found at Myod1 and Olig3 promoters
(Figure 7C). Moreover, upon induction of differentiation, cJun
was now detected at promoters of these EDC genes in WT cells
(Figure 7C). Importantly, inhibition of AP1 binding by TanIIA
reduced the cJun ChIP signal at EDC genes underlying its spec-
ificity (Figure 7D).
Ezh1 Increases in the Epidermis as Ezh2 Wanes:
Partially Overlapping Activities of Ezh2 and Ezh1
Whereas Ezh2 is often expressed during embryogenesis, Ezh1 is
found in adult tissues (Laible et al., 1997; Margueron et al., 2008;
Su et al., 2003). This also holds true for epidermis in which post-
natally, as basal Ezh2 declined, Ezh1 rose (Figures 1 and S8A).
Additionally, although triMeK27-H3 was barely detected in
primary P0 Ezh2 null MK, it increased with passage (Figure S8B).Recently, Ezh1 was shown to function similarly to Ezh2 (Shen
et al., 2008), which could explain the residual triMeK27-H3modi-
fication in Ezh2 cKO epidermis. Although an effective Ezh1
shRNA did not appreciably affect the overall high levels of
triMeK27-H3 in WT MK, it did show a marked effect on further
diminishing triMeK27-H3 marks in passaged Ezh2 null MK
(Figure S8C). Together, these findings suggest that the bulk of
triMeK27-H3 in embryonic and neonatal basal cells is due to
Ezh2 but that Ezh1 can establish this histone mark in the
absence of Ezh2.
Analysis of gene expression further suggested that certain
functions of Ezh1 and Ezh2 in MK might be similar
(Figure S8D). Thus, terminal differentiation genes were upregu-
lated in both Ezh2 null and Ezh1 shRNA cells, and this effect
was even stronger in passaged Ezh2 null/Ezh1 shRNA MK.
Ezh1 was not upregulated in Ezh2 cKO cells either in vivo or
in vitro (Figure S8E), suggesting that both Ezh2 and Ezh1
contribute to repression of terminal differentiation genes. This
could explain why no obvious morphological defects were noted
in the mature skin of our Ezh2 cKO mice in which Ezh1 is
expressed (Figures 3B and S8A). Supportive evidence for this
notion stems from engraftments of primary WT and Ezh2 cKO
MK infected with control or Ezh1 shRNAs. Cells infected selec-
tively with Ezh1, but not control, shRNAs failed to reconstitute
skin in adult mice (Figure S8F). Generation of Ezh1 cKO and
Ezh1/Ezh2 cKO mice will be necessary to further dissect roles
for these developmentally regulated histone methylases in skin
and in other tissues.
DISCUSSION
Molecular mechanisms involving PcG proteins have attracted
significant attention in the stem cell field due to their critical
role in controlling cultured ESCs (Boyer et al., 2006; Lee et al.,
2006; Pasini et al., 2007). By studying the role of Ezh2 in
epidermal development and differentiation, we have uncovered
new insights into the in vivo relevance of PRCs in the context
of lineage determination and differentiation within a tissue. We
have shown that Ezh2-dependent histone modifications act in
embryonic epidermal progenitors to control both proliferative
potential and differentiation. Our results are consistent with
a role for PRCs in mediating repression of Ink4A/Ink4B in
epidermal stem cells and further unveil a role for PRCs in regu-
lating terminal differentiation of these cells by repressing genes
governing epidermal barrier formation.
Our findings are intriguing in light of a recent study reporting
enhanced differentiation of organotypic human epidermal
cultures by overexpressing or RNAi knockdown of the histone
demethylase Jmjd3 (Agger et al., 2007; Sen et al., 2008). In
contrast to Ezh2, Jmjd3 levels do not appear to change in basal
versus suprabasal cells of mouse epidermis. It is tempting to
speculate that suprabasal Jmjd3 might ensure proper differenti-
ation through efficient removal of the Ezh-mediated triMeK27-H3(G and H) By contrast, PMA, which promotes AP1 activity, enhances precocious expression of EDC genes in Ezh2 cKO, but not WT basal cells (G). EDC upre-
gulation in PMA-treated Ezh2 null cells is significantly lower when Jun and JunD are knocked down than in sh control (H). Data are mean ± SD. n = 3. *p < 0.05.
Active K14 and Ppib genes served as controls.
BL, basal layer cells. LowCa, in vitro conditions that prevent differentiation of basal progenitors. HighCa, conditions that promote terminal differentiation.Cell 136, 1122–1135, March 20, 2009 ª2009 Elsevier Inc. 1131
Figure 7. Opposing Roles for PcG Repressors and AP1 Transcriptional Activators in Epidermal Development and Differentiation
(A and B) Semiquantitative RT-PCR shows that EDC genes are induced when WT basal cells commit to terminally differentiate (A), and ChIP analysis (B) shows
that triMeK27-H3 marks associated with EDC genes in basal cells decline upon calcium-induced differentiation. Semiquantitative PCR with primers against
promoter of the active K5 gene was used for normalization (B).
(C and D) ChIP analysis shows cJun recruitment to promoters of late differentiation genes upon removal of Ezh2-dependent triMeK27-H3mark in cKO basal cells
or WT cells upon differentiation (C), but this recruitment is inhibited upon treatment of cells with AP1 inhibitor TanIIA (D). Presence of cJun at the K5 promoter
served as a positive control. No recruitment of cJun toMyod1 andOlig3 promoters that lack obvious AP1 sites was detected. Semiquantitative PCRwith primers
against intergenic region on chromosome 5 was used for normalization. Data are mean ± SD. n = 2. *p < 0.05.
(E) Differential expression of PcG repressor and Ap1 activator ensures spatial and temporal program of epidermal differentiation. In WT basal cells, the presence
of triM3K27-H3 mark prevents AP1 from binding and activation of late differentiation genes. In Ezh2cKO or in differentiated WT cells, loss of triMeK27-H3 mark
allows Ap1 to bind and activate transcription of late differentiation genes.mark, and in the future, it will be interesting to explore the
possible interplay between histone methylases and demethy-
lases in this process. However, from our physiological and
molecular evidence, we favor the view that the primary mecha-
nism for controlling epidermal differentiation in mouse develop-
ment is by temporal expression of histone methylase Ezh2,
which in basal cells, interferes with the recruitment of transcrip-
tional activators to their differentiation-specific targets.
Our study also uncovered several notable differences in the
mechanisms by which PcGs control differentiation in ESCs
versus embryonic epidermal progenitors. In ESCs, triMeK27-1132 Cell 136, 1122–1135, March 20, 2009 ª2009 Elsevier Inc.H3 is present at and globally represses key transcriptional regu-
lators that promote diverse cell lineages (Boyer et al., 2006; Lee
et al., 2006). Such widespread repression is critical since ESCs
are pluripotent. That said, ESCs must also retain the ability to
respond to external cues and activate any one of the differentia-
tion lineages repressed by PcG complexes. Once they make
a commitment to differentiate, they must repress pluripotent
regulators, e.g., Oct4, Nanog, and Sox2, and this process also
appears to be governed either indirectly or directly by PcG-medi-
ated events (Pasini et al., 2007). By contrast, embryonic
epidermal stem cells maintain permanent repression of
pluripotent regulators and selectively activate only the terminal
differentiation program of the skin barrier.
Our results suggest that, like ESCs, embryonic basal progen-
itors use PcG-mediated repression to maintain repression of
both nonepidermal and epidermal differentiation programs.
However, in ESCs, bivalent active and repressive marks exist
over many of the lineage-regulatory genes that are governed
by PRCs, such that once repressive marks are relieved, the
genes are poised to become activated (Pasini et al., 2007). By
contrast, although Ezh2 loss in embryonic basal cells reduced
triMeK27-H3 on many of the same genes as in ESCs, this was
not sufficient for either maintaining or relieving their transcrip-
tional repression. Rather than use a bivalent chromatin mark,
embryonic basal epidermal progenitors appear to employ
PRCs to prevent recruitment of AP1 and perhaps other key tran-
scriptional activators required for terminal differentiation
(Figure 7E). This additional layer of regulation ensures that, as
development proceeds, most lineages remain permanently
silenced while permitting the epidermal lineage to be selectively
activated.
By invoking additional mechanisms to restrict activation of
differentiation programs, developing tissues are poised to take
advantage of relieving PRC modifications as a means to fine-
tune the transcriptional program of the desired lineage. In this
regard, it was notable that Ezh2 was highest in proliferative,
undifferentiated basal cells. Upon induction of the basal-to-
spinous switch, Ezh2 was reduced, and by the time the
spinous-to-granular transcriptional switch was executed, little
or no Ezh2 was detected. By employing gene-specific transcrip-
tional activators that can operate when Ezh2 and triMeK27-H3
wane, the correct differentiation stage genes can be induced,
and the undesirable nonepidermal lineages can remain silenced.
Controlling the balance between proliferation and differentia-
tion requires different challenges in embryonic versus adult
skin. In the rapidly growing embryo, basal proliferation must be
high, and the program of epidermal differentiation and barrier
acquisition must be orchestrated from scratch. By contrast,
during homeostasis of the postnatal epidermis, proliferation
rates are considerably reduced, and the program of terminal
differentiation merely requires maintenance and not establish-
ment. In this regard, it may be relevant that postnatal human
basal epidermal cells exhibit low immunoreactivity to the active
chromatin mark acetylated-H4 and appreciable reactivity to
the repressive chromatin mark triMeK9-H3 (Frye et al., 2007).
Additionally, our studies showing that Ezh2 expression wanes
after birth suggest that either the Ezh2 paralog Ezh1 or alterna-
tive mechanisms come into play to control homeostasis in the
mature epidermis. Although distinguishing between these
possible models in vivo is predicated upon Ezh1 and Ezh1/
Ezh2 double cKO mice, our in vitro and engraftment studies
suggest that Ezh2 may provide the bulk of triMeK27-H3 modifi-
cation in basal epidermal cells, and Ezh1 may function in fine-
tuning histone modifications at later stages of terminal differen-
tiation during embryogenesis and in homeostasis of postnatal
epidermis.
In closing, it is worth considering the potential clinical impact
of our findings. The epidermal barrier does not form until shortly
before birth. Prematurely born infants lack this essential shield,and hence, accelerating barrier acquisition becomes a critical
necessity in reducing the medical risks of these infants. Our
discovery that conditional loss of Ezh2 accelerates epidermal
barrier formation in the embryo but does not impair postnatal
development offers a hitherto unanticipated target for the devel-
opment of therapies that might be useful to infant survival. More-
over, Ezh2’s exquisite ability to function in rapidly proliferating,
tissue-restricted progenitor cells provides an intriguing explana-
tion for why Ezh2 is overexpressed in many tumors wherein
hyperproliferation and reduced differentiation are often likened
to an embryonic state.
EXPERIMENTAL PROCEDURES
Mice, BrdU Injections, and Barrier Assays
Mice were housed in the ALAAC accredited CBC animal facility at The Rock-
efeller University in accordance with university and NIH guidelines. Mice
conditionally ablated for Ezh2 in skin were generated by mating Ezh2fl/fl mice
(Su et al., 2003) with K14-Cre mice (Vasioukhin et al., 1999). Genotyping was
confirmed by PCR of tail skin DNAs. BrdU (Sigma-Aldrich) was administered
to pregnant mice or to neonatal pups by peritoneal injection (50 mg/g BrdU).
Dye exclusion assays were performed as described (Hardman et al., 1998).
Fluorescence-Activated Cell Sorting
FACS purification of epidermal cells from K14-H2B-GFP embryos was per-
formed on a FACSVantage SE system equipped with FACS DiVa software
(BD Biosciences). Cells were gated for single events and viability and then
sorted according to a6 integrin expression and GFP. Cell-cycle/BrdU incorpo-
ration was analyzed using the BrdU-FITC Flow Kit (PharMingen) (see Blanpain
et al., 2004), and cell-cycle status was analyzed using FlowJo program.
Microarray Analysis
RNAs from FACS-purified WT and Ezh2 cKO basal cells (see Supplemental
Experimental Procedures) were provided to the Genomics Core Facility,
MSKCC for quality control, quantification, reverse transcription, labeling,
and hybridization to MOE430A 2.0 microarray chips (Affymetrix). Arrays
were scanned per the manufacturer’s specifications for the Affymetrix
MOE430v2 chip. Images were background subtracted, and probeset expres-
sion estimates were generated using the MAS5 algorithm implemented in Bio-
conductor. A detection p value of p = 0.05 was used to threshold probesets
into present (p% 0.05) or absent (p > 0.05). Probesets were identified as differ-
entially expressed when the absolute fold change was > 2, and the probeset is
present in both samples of the relatively overexpressed group. Probesets
selected for visualization were log2 transformed and normalized to the repli-
cate mean (estimated from basal cells). Intensity bias between replicates
necessitated this within replicate normalization, which leaves the data for
each gene centered around zero in the basal cells. These normalized data
were analyzed with hierarchical clustering (Pearson correlation, average
linkage) and visualized with heatmaps to assist in interpretation.
Statistics
For all graphs, mean value ± one standard deviation was presented with the
number of replicates indicated in figure legends. To determine significance
between two groups indicated in figures by a bracket, comparisons were
made using Student’s t test. For all statistical tests, the 0.05 level of confidence
was accepted for statistical significance.
Cell Culture
Enzymatic separation of epidermis from skins and primary P0 MK culturing
were as described (Blanpain et al., 2004). To visualize colonies, we fixed cells
and stained them with 1% Rhodamine B (Sigma). To induce differentiation in
culture, calcium was raised from 0.05 to 1.5 mM. To assess cell growth, we
plated equal numbers of live cells on collagen-coated 6-well plates. Cell
numbers were determined by hemocytometer.Cell 136, 1122–1135, March 20, 2009 ª2009 Elsevier Inc. 1133
To assess AP1 function, MKwere treated either with Tanshinone IIA (Biomol)
for 48 hr with indicated concentrations or with PMA (Sigma) 10 ng/ml for
5–10 hr. DMSO or Ethanol were used as vehicle controls, correspondingly.
To attenuate cJun and JunD, cells were infected with lentiviruses that carry
shRNA constructs (Sigma). Selection with puromyocin (2 mg/ml) was done
2 days upon infection, and MK were analyzed a week after infection.
Chromatin Immunoprecipitation Assays
Assays were performed with the EZ ChIP kit (Millipore). Briefly, 2 3 106 cells
were crosslinked with 1% formaldehyde for 10 min at room temperature (for
ChIPs with Ezh2, H3, and triMeK27-H3 Abs) or for 15 min at 37C (for cJun
Abs). Cells were collected, lysed, and sonicated for a total of 200 s using Bran-
son Sonifier 450 equipped with microtip (setting 3; 50% input). Chromatin
lysates were used for immunoprecipitations with either Ezh2 (Lake Placid Bio-
logicals), triMeK27-He (Upstate), H3 (Abcam), triMeK4-H3 (Abcam), cJun
(Santa Cruz), or no Ab control. Immunoprecipitates were collected with Protein
A/G agarose beads (Millipore), protein/DNA crosslinks were reversed by incu-
bating at 65C, and DNA was purified using QIAgen PCR purification kit (QIA-
gen). Treatment with TanIIa drug for ChIP was done for 2 hr with 100 mM of
TanIIa or DMSO (vehicle control).
ChIP DNA was analyzed by performing quantitative PCR as described
above. Primers against K5 and/or intergenic region on chromosome 5 genes
were used for normalization. Sequences of primers are available upon request.
ACCESSION NUMBERS
Microarray data of genes expressed in basal WT and Ezh2cKO cells at E16
have been deposited to the GEO repository under GSE14045 Series Acces-
sion Number.
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